KR960705545A - Charged Liposome Preparation - Google Patents

Abstract

The present invention provides a method for administering a liposome preparation comprising the electrically charged component in an amount effective to reduce the adverse effects of the liposome preparation, such as hal hydrodynamic effects, and increase host resistance.

Description

Charged Liposome Preparation

Since this is an open matter, no full text was included.

FIG. 1 is a schematic of the ethanol evaporation method for the preparation of liposomes. FIG. 2 is the average after intravenous injection of liposomes prepared from different lipids (300 ng lipid / kg, 100 mg / lipid / kg / min) and mannitol (300 mM) Blood pressure (% of pretreatment value) n = 6, means ± SEM, FIG. 3 shows intravenous infusion of liposomes prepared from different lipids (300 ng lipid / kg, 100 mg / lipid / kg / min) and mannitol (300 mM) Total peripheral resistance (% of pretreatment value), n = 6, means ± SEM, FIG. 4 shows intravenous liposomes prepared from different lipids (300 ng lipid / kg, 100 mg / lipid / kg / min) and mannitol (300 mM) Final diastolic blood pressure (EDP) after infusion, n = 6, means ± SEM.

Claims (32)

In a method for reducing the hemodynamic effect of a parenterally administrable liposome preparation which may cause a hemodynamic effect when administered to a mammal, the amount of the electrically charged component effective in reducing the hemodynamic effect The amount is added to any amount of said component in said liposome formulation). In addition to the optional amount of the electrically charged component in the liposome preparation, the component is incorporated into the liposome preparation in an amount effective to improve the host's resistance to the parenterally administrable liposome preparation. How to improve resistance. A method of administering an active agent encapsulated in a liposome preparation having a systemic adverse effect, wherein the amount of the electrically charged component effective to reduce systemic adverse effects is added to any amount of the component in the liposome formulation. A method for administering an active agent enclosed in a liposome preparation having a systemic adverse effect, characterized in that the liposome preparation is confused with the prior art. A method of imaging host organism tissue comprising administering an active agent encapsulated in a liposome preparation having a systemic adverse effect, the amount of the electrically charged component being effective to reduce systemic adverse effects, the amount being in the liposome preparation. Liposome formulation is mixed prior to administration to an amount of A method for reducing the hemodynamic effect of a parenterally administrable liposome preparation, comprising administering a liposome preparation comprising an electrically charged component in an amount effective to reduce the hemodynamic effect in combination with liposome administration. The method of claim 1 wherein the electrically charged component is negatively charged. The method of claim 1 wherein the electrically charged component is a fatty acid. The method of claim 1 wherein the electrically charged component is stearic acid. The method of claim 1, wherein the liposome further comprises an active agent. The method of claim 1, wherein the liposome further comprises a contrast agent. The method of claim 1, wherein the contrast agent is iopromide. For liposomes that do not contain an electrically charged component and have a systemic adverse effect when administered to a mammal, the amount of the electrically charged component effective to reduce the systemic effect (this amount is any of the components in the liposome formulation) Liposomes, characterized in that the incorporation of the liposomes). 13. The liposome according to claim 12 wherein the electrically charged component is negatively charged. 13. The liposome of claim 12 wherein the electrically charged component is a fatty acid. The liposome of claim 12 wherein the electrically charged component is stearic acid. 13. The liposome of claim 12 wherein the liposome further comprises an active agent. The liposome of claim 12 wherein the liposome further comprises a contrast agent. For liposomes that have a systemic adverse effect when administered to a mammal, including an electrically charged component, the amount of the electrically charged component effective to reduce the systemic effect (this amount is any of the components in the liposome formulation Liposomes, characterized in that the incorporation of the liposomes). The liposome of claim 18 wherein the electrically charged component is negatively charged. The liposome according to claim 18 wherein the electrically charged component is a fatty acid. The liposome according to claim 18 wherein the electrically charged component is stearic acid. The liposome according to claim 18 further comprising an active agent. 19. The liposome according to claim 18 further comprising a contrast agent. A method of administering a therapeutic agent enclosed in a liposome preparation having a systemic adverse effect, wherein the amount of the electrically charged component effective to reduce the systemic adverse effect is added to any amount of the component in the liposome formulation. To a liposome preparation having a systemic adverse effect, characterized in that it is incorporated into the liposome preparation before administration. The method of claim 1 wherein the electrically charged component incorporated into the liposome formulation is stearic acid, which component is incorporated in an amount such that the liposomes comprise phosphatidylcholine, cholesterol and stearic acid in a molar ratio of 4: 5: 1 each. How. The method of claim 1, wherein the electrically charged component incorporated into the liposome formulation is stearic acid, which component is incorporated in an amount such that the liposome comprises phosphatidylcholine and stearic acid in a molar ratio of about 9: 1 each. . The method of claim 1, wherein the electrically charged component incorporated into the liposome formulation is DSPG, which component is incorporated in an amount such that the liposomes comprise DSPC and DSPG in a molar ratio of 9: 1, respectively. The method of claim 1 wherein the electrically charged component is DSPG. The method of claim 5, wherein the electrically charged component is DSPG. The method of claim 12, wherein the electrically charged component is DSPG. The method of claim 24, wherein the electrically charged component is DSPG. Identify liposome preparations having a hemodynamic adverse effect and liposomes in an amount effective to reduce the hemodynamic effect of the electrically charged ingredient, which amount is added to any amount of the ingredient in the liposome preparation. A method for reducing the hemodynamic effect of a parenterally administrable liposome formulation, which may result in a hemodynamic effect when administered to a mammal, wherein the formulation is confused with the formulation. ※ Note: The disclosure is based on the initial application.